Bristol Myers' Opdivo leads the pack with FDA approval for resected esophageal or GEJ cancer

In a first for immunotherapies, Bristol Myers Squibb’s PD-1 blockbuster Opdivo (nivolumab) won another FDA approval on Thursday, this time for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy.